Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain

A 13-week, randomized, placebo-controlled trial

Amy S. Chappell, Melissa J. Ossanna, Hong Liu-Seifert, Smriti Iyengar, Vladimir Skljarevski, Linda Chunhong Li, Robert (Rob) Bennett, Harry Collins

    Research output: Contribution to journalArticle

    164 Citations (Scopus)

    Abstract

    Pain is a common cause of disability in osteoarthritis. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has demonstrated analgesic effects in diabetic peripheral neuropathy and fibromyalgia. Considering its central mechanism of action, duloxetine may be effective in other pain states with evidence of central sensitization. Herein, we report the results of a 13-week, randomized, double-blind, placebo-controlled trial of duloxetine (60-120 mg/day) versus placebo in the treatment of knee pain in 231 patients meeting clinical and radiographic criteria for osteoarthritis of the knee. Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24-h pain scores) beginning at Week 1 and continuing through the treatment period (P ≤ .05). There was also a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes. Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo).

    Original languageEnglish (US)
    Pages (from-to)253-260
    Number of pages8
    JournalPain
    Volume146
    Issue number3
    DOIs
    StatePublished - Dec 5 2009

    Fingerprint

    Knee Osteoarthritis
    Analgesics
    Randomized Controlled Trials
    Placebos
    Pain
    Central Nervous System Sensitization
    Therapeutics
    Fibromyalgia
    Diabetic Neuropathies
    Peripheral Nervous System Diseases
    Osteoarthritis
    Knee
    Duloxetine Hydrochloride

    Keywords

    • Duloxetine
    • Osteoarthritis
    • Pain

    ASJC Scopus subject areas

    • Clinical Neurology
    • Anesthesiology and Pain Medicine
    • Neurology
    • Pharmacology

    Cite this

    Chappell, A. S., Ossanna, M. J., Liu-Seifert, H., Iyengar, S., Skljarevski, V., Li, L. C., ... Collins, H. (2009). Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain, 146(3), 253-260. https://doi.org/10.1016/j.pain.2009.06.024

    Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain : A 13-week, randomized, placebo-controlled trial. / Chappell, Amy S.; Ossanna, Melissa J.; Liu-Seifert, Hong; Iyengar, Smriti; Skljarevski, Vladimir; Li, Linda Chunhong; Bennett, Robert (Rob); Collins, Harry.

    In: Pain, Vol. 146, No. 3, 05.12.2009, p. 253-260.

    Research output: Contribution to journalArticle

    Chappell, AS, Ossanna, MJ, Liu-Seifert, H, Iyengar, S, Skljarevski, V, Li, LC, Bennett, RR & Collins, H 2009, 'Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial', Pain, vol. 146, no. 3, pp. 253-260. https://doi.org/10.1016/j.pain.2009.06.024
    Chappell, Amy S. ; Ossanna, Melissa J. ; Liu-Seifert, Hong ; Iyengar, Smriti ; Skljarevski, Vladimir ; Li, Linda Chunhong ; Bennett, Robert (Rob) ; Collins, Harry. / Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain : A 13-week, randomized, placebo-controlled trial. In: Pain. 2009 ; Vol. 146, No. 3. pp. 253-260.
    @article{3717df69e2644b42a10ba4ed79795d5e,
    title = "Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial",
    abstract = "Pain is a common cause of disability in osteoarthritis. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has demonstrated analgesic effects in diabetic peripheral neuropathy and fibromyalgia. Considering its central mechanism of action, duloxetine may be effective in other pain states with evidence of central sensitization. Herein, we report the results of a 13-week, randomized, double-blind, placebo-controlled trial of duloxetine (60-120 mg/day) versus placebo in the treatment of knee pain in 231 patients meeting clinical and radiographic criteria for osteoarthritis of the knee. Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24-h pain scores) beginning at Week 1 and continuing through the treatment period (P ≤ .05). There was also a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes. Adverse-event rates did not differ significantly between treatment groups (49.5{\%} for duloxetine 60-120 mg/day, and 40.8{\%} for placebo).",
    keywords = "Duloxetine, Osteoarthritis, Pain",
    author = "Chappell, {Amy S.} and Ossanna, {Melissa J.} and Hong Liu-Seifert and Smriti Iyengar and Vladimir Skljarevski and Li, {Linda Chunhong} and Bennett, {Robert (Rob)} and Harry Collins",
    year = "2009",
    month = "12",
    day = "5",
    doi = "10.1016/j.pain.2009.06.024",
    language = "English (US)",
    volume = "146",
    pages = "253--260",
    journal = "Pain",
    issn = "0304-3959",
    publisher = "Elsevier",
    number = "3",

    }

    TY - JOUR

    T1 - Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain

    T2 - A 13-week, randomized, placebo-controlled trial

    AU - Chappell, Amy S.

    AU - Ossanna, Melissa J.

    AU - Liu-Seifert, Hong

    AU - Iyengar, Smriti

    AU - Skljarevski, Vladimir

    AU - Li, Linda Chunhong

    AU - Bennett, Robert (Rob)

    AU - Collins, Harry

    PY - 2009/12/5

    Y1 - 2009/12/5

    N2 - Pain is a common cause of disability in osteoarthritis. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has demonstrated analgesic effects in diabetic peripheral neuropathy and fibromyalgia. Considering its central mechanism of action, duloxetine may be effective in other pain states with evidence of central sensitization. Herein, we report the results of a 13-week, randomized, double-blind, placebo-controlled trial of duloxetine (60-120 mg/day) versus placebo in the treatment of knee pain in 231 patients meeting clinical and radiographic criteria for osteoarthritis of the knee. Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24-h pain scores) beginning at Week 1 and continuing through the treatment period (P ≤ .05). There was also a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes. Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo).

    AB - Pain is a common cause of disability in osteoarthritis. Duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), has demonstrated analgesic effects in diabetic peripheral neuropathy and fibromyalgia. Considering its central mechanism of action, duloxetine may be effective in other pain states with evidence of central sensitization. Herein, we report the results of a 13-week, randomized, double-blind, placebo-controlled trial of duloxetine (60-120 mg/day) versus placebo in the treatment of knee pain in 231 patients meeting clinical and radiographic criteria for osteoarthritis of the knee. Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24-h pain scores) beginning at Week 1 and continuing through the treatment period (P ≤ .05). There was also a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes. Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo).

    KW - Duloxetine

    KW - Osteoarthritis

    KW - Pain

    UR - http://www.scopus.com/inward/record.url?scp=70350619997&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=70350619997&partnerID=8YFLogxK

    U2 - 10.1016/j.pain.2009.06.024

    DO - 10.1016/j.pain.2009.06.024

    M3 - Article

    VL - 146

    SP - 253

    EP - 260

    JO - Pain

    JF - Pain

    SN - 0304-3959

    IS - 3

    ER -